Work Here?
Jade Biosciences
Work Here?
Develops, licenses, and commercializes biologic therapies
Jade Biosciences
Work Here?
Develops, licenses, and commercializes biologic therapies
Overview
Jade Biosciences develops and commercializes biologic therapies. It builds a pipeline of potentially best-in-class biologics and advances them from discovery to market, using research, development, and strategic collaborations. Its products are engineered biologics—lab-made medicines designed to interact with the body's systems to treat diseases for which there are unmet medical needs. The company differentiates itself through its backing from Paragon Therapeutics and Fairmount, and by leveraging Paragon’s discovery-stage assets to pursue a focused pipeline with potential partnerships and licensing opportunities. Its goal is to bring effective biologic treatments to patients, generate revenue from product sales, licensing deals, and partnerships, and protect patient data while working with compliant support providers.
About Jade Biosciences
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Post IPO Equity
Headquarters
Waltham, Massachusetts
Founded
2024
People at Jade Biosciences
People at Jade Biosciences who can refer or advise you
Simplify's Take
What believers are saying
- Phase 2 JUNIPER trial for JADE101 started May 2026; interim data expected in 2027 for Phase 3 planning.
- Secured $336M cash runway into first half of 2028, enabling clinical trials, manufacturing, and R&D investments.
- $150M public offering plus $45M BB Biotech private placement ensures capital for Phase 3 and regulatory advancement.
What critics are saying
- JADE101 fails Phase 2 for IgA nephropathy due to insufficient APRIL inhibition or safety events; 40–55% probability in 12–18 months.
- Paragon Therapeutics revokes licensing rights for JADE101/201/301 due to IP dispute, halting all pipeline progress; 20–35% probability in 12–24 months.
- BB Biotech forces dilutive secondary sale of public shares at <$12, triggering market panic and stock collapse to <$8; 35–50% probability in 6–12 months.
What makes Jade Biosciences unique
- JADE101 uniquely blocks APRIL with ~70% IgA reduction sustained at 12 weeks, no serious adverse events.
- Company advances multiple antibody candidates for autoimmune diseases, including JADE201 targeting BAFF-R in preclinical stage.
- Board includes Dr. Mark Eisner, adding 25+ years of clinical development and regulatory strategy expertise in immunology.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$410M
Above
Industry Average
Funded Over
4 Rounds
Growth & Insights and Company News
6 month growth
↑ 27%1 year growth
↑ 27%2 year growth
↑ 48%SAN FRANCISCO and VANCOUVER, British Columbia, June 03, 2026 (GLOBE NEWSWIRE) — Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced the pricing of a public offering of 10,000,000 shares of its common stock. The shares of common stock are being … Continued
Jade Biosciences is Hiring for 10 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Jade Biosciences
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Post IPO Equity
Headquarters
Waltham, Massachusetts
Founded
2024
Jade Biosciences is Hiring for 10 Jobs on Simplify!
Find jobs on Simplify and start your career today